News & Trends - Medical Technology

Brisbane-based LTR Medical secures exclusive distributor agreement

Health Industry Hub | September 14, 2020 |
[Total: 1    Average: 4/5]

MedTech News: Brisbane-based LTR Medical secures exclusive distributor agreement for Medovate’s SAFIRA (SAFer Injection for Regional Anaesthesia) in Australia and New Zealand.

Developed in collaboration with anaesthetists, SAFIRA is set to help revolutionise standard regional anaesthesia clinical practice. With the use of regional anaesthesia continuing to grow significantly in Australia and New Zealand, SAFIRA has the potential to make a significant impact.

Amid the current COVID-19 pandemic, recent publications have recommended regional anaesthesia be considered whenever surgery is planned for a suspected or confirmed COVID-19 patient. This is because regional anaesthesia preserves respiratory function and avoids aerosolisation and the potential for transmission of COVID-19 compared to general anaesthesia.

Already launched across the United States, this distribution agreement to bring SAFIRA to market in Australia and New Zealand marks a significant further step in making this new medical technology available to healthcare providers to help deliver improved patient care and cost saving benefits.

Chris Rogers, Sales and Marketing Director, Medovate, said “We are delighted to have reached agreement with LTR Medical who have the necessary experience in bringing innovative new medical devices to market, which was a key consideration for us. This partnership will now ensure that the clinical, patient safety and cost savings benefits that we believe SAFIRA offers will now be available to regional anaesthetists in Australia and New Zealand. Medovate are looking forward to working with Lee, Danny and the wider LTR Medical team.”

Danny Zanardo, VP Commercial LTR Medical, commented “The team at LTR Medical are excited to partner with Medovate and bring SAFIRA to Anaesthetists and patients in the Australian and New Zealand Markets. We believe the SAFIRA technology is disruptive in context of improving workflow, improving safety and reducing risk in regional anaesthesia techniques. We look forward to a long term collaboration with Medovate.”

The new SAFIRA device revolutionises current practice in a number of ways. First, it makes the current two-person procedure a one-person procedure by giving anaesthetists full control and frees up resources.

The technology also incorporates a unique safety feature that helps reduce the risk of nerve damage as anaesthetic is prevented from being injected at pressures above 20psi. This reduces the need for follow up management of nerve damage.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Sustained COVID-19 impact on cancer services and procedures

Sustained COVID-19 impact on cancer services and procedures

Health Industry Hub | January 15, 2021 |

MedTech News: Cancer Australia has released the latest in a series of reports analysing for the first time the significance […]

More


News & Trends - Medical Technology

MedTech News - Healthscope hospital leading in high-tech medical surgery

Healthscope hospital leading in high-tech medical surgery

Health Industry Hub | January 15, 2021 |

MedTech News: Healthscope’s Knox Private Hospital recently celebrated two key milestones, underscoring its reputation as a leading proponent of high-tech […]

More


News & Trends - Pharmaceuticals

Pharma News - Experts comment on AstraZeneca vaccine efficacy concerns

Experts comment on AstraZeneca vaccine efficacy concerns

Health Industry Hub | January 15, 2021 |

Pharma News: In light of the comments made regarding AstraZeneca’s COVID-19 vaccine efficacy by the Australian and New Zealand Society […]

More


Communication

Communication Pharma Biotech Medtech - Secrets of persuasion to influence anyone

Secrets of persuasion to influence anyone

Health Industry Hub | January 15, 2021 |

To understand the art of persuasion, you can turn to cognitive science for guidance in dealing with the unconscious mind. […]

More